For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.).
Scope of the Report:
This report focuses on the Bacterial Conjunctivitis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The development of multi-drug resistant variants, which is resulting in the augmented use of drugs, is expected to boost market growth during the forecast period. Microbes such as Streptococcus or Staphylococcus are responsible for bacterial conjunctivitis. These microbes change themselves chemically to develop resistance to the drugs. Since this resistance develops due to the irrational use of antibiotics, it may lead to severe complications in the body of the patients. Patients are thus expected to take up more medications such as corticosteroids and higher doses of antibiotics for the treatment of such diseases. This augmented use of drugs like corticosteroids and antibiotics for the treatment of bacterial conjunctivitis will propel the prospects for growth in this market.
The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.
The rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market's growth over the coming years.
The worldwide market for Bacterial Conjunctivitis Drugs is expected to grow at a CAGR of roughly -3.6% over the next five years, will reach 350 million US$ in 2023, from 430 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Santen Pharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Infective (Viral and Bacterial)
- Irritant (Chemical)
There are 15 Chapters to deeply display the global Bacterial Conjunctivitis Drugs market.
Chapter 1, to describe Bacterial Conjunctivitis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Bacterial Conjunctivitis Drugs, with sales, revenue, and price of Bacterial Conjunctivitis Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Bacterial Conjunctivitis Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Bacterial Conjunctivitis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Bacterial Conjunctivitis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source